Bidard et al 1 reported that elacestrant, an oral selective estrogen receptor (ER) degrader (SERD), improved the progression-free survival (PFS) in patients with pretreated ER-positive/human epidermal ...
View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
Asieris Pharmaceuticals Co. Ltd. has identified compounds acting as inhibitors of CDK1/cyclin A2, CDK2/cyclin E1, CDK4/cyclin D1 and CDK6/cyclin D1 reported to be useful for the treatment of breast ...
Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results